News und Analysen

Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) have a lot in common. Both companies are among the leaders in the biotech industry. Both have deep lineups and pipelines. And both are looking to

While government programs help retirees replace some of their income once they stop working, these initiatives aren't meant to fund all of people's expenses in their golden years. That's why many

The latest rise in COVID-19 statistics is bringing investors back to coronavirus stocks. That, combined with a top-down effort to develop an updated vaccine and get it in the arms of as many

Growth stocks are back in style after getting battered in last year's downturn. Some, though, never went out of fashion in the first place. That's the case with this trio of biotech stocks: Vertex

Growth stocks are back in style after getting battered in last year's downturn. Some, though, never went out of fashion in the first place. That's the case with this trio of biotech stocks: Vertex

Growth stocks are back in style after getting battered in last year's downturn. Some, though, never went out of fashion in the first place. That's the case with this trio of biotech stocks: Vertex

Growth stocks have lost momentum in August after a strong start to the year. The market is worried about the impact of a possible recession, high inflation, and high interest rates on the future

Despite what many people think, the pandemic isn't officially over yet. And while the world has made tremendous progress, the coronavirus continues to cause problems. COVID-19 cases and

"I don't get no respect." That was the line the late comedian Rodney Dangerfield made famous. But it could also apply to some stocks.

Three Motley Fool contributors identified surprisingly

Shares of Premier (NASDAQ: PINC) are down 15.5% this week as of 12:05 p.m. ET Friday, according to data provided by S&P Global Market Intelligence, after the healthcare-improvement leader announced

There's a lot going on with biotech giant Regeneron (NASDAQ: REGN) that may be of interest to investors. The company could soon face biosimilar competition from one of its key growth drivers, Eylea

There's a lot going on with biotech giant Regeneron (NASDAQ: REGN) that may be of interest to investors. The company could soon face biosimilar competition from one of its key growth drivers, Eylea

There's a lot going on with biotech giant Regeneron (NASDAQ: REGN) that may be of interest to investors. The company could soon face biosimilar competition from one of its key growth drivers, Eylea

Companies that can withstand market volatility make for good long-term investments. Ireland-based Medtronic (NYSE: MDT), a major player in the medical device industry, has repeatedly demonstrated

Analysts' price targets can help investors get an idea of whether there's a lot of bullishness surrounding a stock. But in some cases, a high upside can simply be due to elevated price targets that

If you're looking for a high-yield dividend stock in the healthcare sector, you might be interested in comparing Takeda Pharmaceutical (NYSE: TAK) and Viatris (NASDAQ: VTRS).

Both companies offer

If you're looking for a high-yield dividend stock in the healthcare sector, you might be interested in comparing Takeda Pharmaceutical (NYSE: TAK) and Viatris (NASDAQ: VTRS).

Both companies offer

Shares of Medtronic (NYSE: MDT) fell 3.1% on Thursday, according to data provided by S&P Global Market Intelligence, giving back yesterday's post-earnings gains after it announced advisors to the

Retirement is a big problem for many Americans. According to a recent poll from BlackRock, just 56% of people believe that they will be able to retire comfortably and have the life they want in

Retirement is a big problem for many Americans. According to a recent poll from BlackRock, just 56% of people believe that they will be able to retire comfortably and have the life they want in